Abstract
The use of natural compounds is an interesting stratagem in the search of drugs with therapeutic potential for the treatment of Alzheimers disease (AD). We report here the effect of the hyperforin derivative (IDN5706, tetrahydrohyperforin), a semi-synthetic derivative of the St. Johns Wort, on the brain neuropathology, learning and memory in a double transgenic (APPswe, PS-1dE9) mouse model of AD. Results indicate that, IDN5706 alleviates memory decline induced by amyloid-β (Aβ) deposits as indicated by the Morris water maze paradigm. Moreover, the analysis of Aβ deposits by immunodetection and thioflavin-S staining of brain sections, only reveals a decrease in the frequency of the largersize Aβ deposits, suggesting that IDN5706 affected the turnover of amyloid plaques. Immunohistochemical analysis, using GFAP and n-Tyrosine indicated that the hyperforin derivative prevents the inflammatory astrocytic reaction and the oxidative damage triggered by high Aβ deposit levels. We conclude that the hyperforin derivative, IDN5706, has therapeutic potential for prevention and treatment of AD.
Keywords: Hyperforin derivative, Alzheimer disease, spatial learning, neuropathological damage, amyloid-β-peptide, oxidative damage, transgenic mice, St. John's wort
Current Alzheimer Research
Title: The Hyperforin Derivative IDN5706 Occludes Spatial Memory Impairments and Neuropathological Changes in a Double Transgenic Alzheimers Mouse Model
Volume: 7 Issue: 2
Author(s): W. Cerpa, J. L. Hancke, P. Morazzoni, E. Bombardelli, A. Riva, P. P. Marin and N. C. Inestrosa
Affiliation:
Keywords: Hyperforin derivative, Alzheimer disease, spatial learning, neuropathological damage, amyloid-β-peptide, oxidative damage, transgenic mice, St. John's wort
Abstract: The use of natural compounds is an interesting stratagem in the search of drugs with therapeutic potential for the treatment of Alzheimers disease (AD). We report here the effect of the hyperforin derivative (IDN5706, tetrahydrohyperforin), a semi-synthetic derivative of the St. Johns Wort, on the brain neuropathology, learning and memory in a double transgenic (APPswe, PS-1dE9) mouse model of AD. Results indicate that, IDN5706 alleviates memory decline induced by amyloid-β (Aβ) deposits as indicated by the Morris water maze paradigm. Moreover, the analysis of Aβ deposits by immunodetection and thioflavin-S staining of brain sections, only reveals a decrease in the frequency of the largersize Aβ deposits, suggesting that IDN5706 affected the turnover of amyloid plaques. Immunohistochemical analysis, using GFAP and n-Tyrosine indicated that the hyperforin derivative prevents the inflammatory astrocytic reaction and the oxidative damage triggered by high Aβ deposit levels. We conclude that the hyperforin derivative, IDN5706, has therapeutic potential for prevention and treatment of AD.
Export Options
About this article
Cite this article as:
Cerpa W., Hancke L. J., Morazzoni P., Bombardelli E., Riva A., Marin P. P. and Inestrosa C. N., The Hyperforin Derivative IDN5706 Occludes Spatial Memory Impairments and Neuropathological Changes in a Double Transgenic Alzheimers Mouse Model, Current Alzheimer Research 2010; 7 (2) . https://dx.doi.org/10.2174/156720510790691218
DOI https://dx.doi.org/10.2174/156720510790691218 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Withdrawal Notice: A Panoramic View on the Phytochemical, Nutritional and Therapeutic value of Ziziphus mauritiana Lam.: A Comprehensive Review
Mini-Reviews in Medicinal Chemistry Pharmacological Neuroprotective Therapy for Acute Spinal Cord Injury: State of the Art
Mini-Reviews in Medicinal Chemistry Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Evaluation of in vivo Anti-inflammatory and Analgesic Activities of Novel Derivatives of Ugi-4CR
Mini-Reviews in Medicinal Chemistry Anti-Inflammatory Activity of Tetracyclines: Applications to Human Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Bioavailability of Quercetin: Problems and Promises
Current Medicinal Chemistry Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia
Current Pharmaceutical Design Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design Glutamate as a Modulator of Embryonic and Adult Neurogenesis
Current Topics in Medicinal Chemistry Pharmacological, Immunological, and Gene Targeting of the Renin-Angiotensin System for Treatment of Cardiovascular Disease
Current Pharmaceutical Design The Seek of Neuroprotection: Introducing Cannabinoids
Recent Patents on CNS Drug Discovery (Discontinued) Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered
Current Medicinal Chemistry Sigma-1 Receptors and Selective Serotonin Reuptake Inhibitors: Clinical Implications of their Relationship
Central Nervous System Agents in Medicinal Chemistry A Potential Role for the Existence of Pericytes in the Neurovascular Unit of the Sexually Dimorphic Nucleus of the Rat Preoptic Area to Control Blood-Brain Barrier Function
Current Neurovascular Research Recent Advances in the Design and Synthesis of Prednisolone and Methylprednisolone Conjugates
Current Pharmaceutical Design Advances in Extracorporeal Detoxification by MARS Dialysis in Patients with Liver Failure
Current Medicinal Chemistry Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal A Mechanistic Rationale for PDE-4 Inhibitors to Treat Residual Cognitive Deficits in Acquired Brain Injury
Current Neuropharmacology